Talk to usTalk to us
Language: EN
Talk to us

Your company, covered like a blue chip

Equity research on listed companies. Every report free to investors.

Institutions managing more than $36 trillion work with our research.

Talk to us Get your company covered Read our research
Loads from Stockdio in the USA: Stockdio receives your IP address, without EU-level data protection.Privacy policy
10 NovZaptecSales rose 39% in Zaptec's usual low quarter for orders9 NovLuberefBest nine months yet, earned through the disruption; Growth II now in 20273 NovBaladnaProfit before portfolio gains up 20% in nine months12 OctSirnaomicsThe RNAimmune money is in, and the FDA has answered in writing on STP70529 SepAinosA partner pays for VELDONA, and Ainos keeps the platform16 SepAinosA front-end customer starts ordering, and the dataset passes a billion12 AugSpinneysThe estate grew 17%; the recovery needs no capital

Highlights from our research

Every report, free and in full. Released to all investors at the same moment.

ZaptecOslo Børs10 November 2026

Q3 is Zaptec's quietest quarter for orders, and this one still brought record sales.

What happened
Revenue rose 39% to NOK 512m in the third quarter reported on 4 November, and EBITDA reached NOK 60m from NOK 21m.
Our view
At NOK 58.30 the price assumes Zaptec grows 1.9% a year for ever, about half the 3.5% in our value.
What to watch
Q4 orders, which we expect at about NOK 850m against NOK 645m a year ago, and Q4 results on 17 February 2027.
Read the reportAsk this report in your own AI

Every report carries its full disclosures.

  1. Fourth quarter 2026
  2. Ask this report

    Zaptec Update

    Sales rose 39% in Zaptec's usual low quarter for orders (PDF, opens in a new tab)

  3. Ask this report

    Luberef Update

    Best nine months yet, earned through the disruption; Growth II now in 2027 (PDF, opens in a new tab)

  4. Ask this report

    Baladna Update

    Profit before portfolio gains up 20% in nine months (PDF, opens in a new tab)

  5. Ask this report

    Sirnaomics Update

    The RNAimmune money is in, and the FDA has answered in writing on STP705 (PDF, opens in a new tab)

  6. Third quarter 2026
  7. Ask this report

    Ainos Update

    A partner pays for VELDONA, and Ainos keeps the platform (PDF, opens in a new tab)

  8. Ask this report

    Ainos Update

    A front-end customer starts ordering, and the dataset passes a billion (PDF, opens in a new tab)

  9. Ask this report

    Spinneys First half 2026 update

    The estate grew 17%; the recovery needs no capital (PDF, opens in a new tab)

Every report carries its full disclosures.

All research

Let your own AI question us

A full report, understood in minutes. Open any report in ChatGPT, Claude, Google AI, Perplexity or Grok, with eight questions to start. The answers are your AI’s. The research behind them is ours.

The cover of a VASRO report: only the VASRO masthead is sharp, the content is blurred
On the cover of every new report.

In three sentences: what is this report’s view, and what is it based on?

Ask this report in your own AI

Latest report: Zaptec, 10 November 2026

  1. The report

    Free, in full. Permission granted.

  2. Your AI opens

    With the report and the question already written.

  3. The answers

    They name the pages. Follow up as you like.

Open your AI (opens in a new tab)

If your AI cannot open the link, download the PDF and add it to the chat.

Pick another report
  • In your own language.
  • Eight questions, written by us.
  • Five AIs, the question ready.

Fast answers are everywhere. Understanding a business takes work.

For us, the highest standard means finding what the numbers really say about a business, and what no quick answer can tell you.

For new research by email, write to info@vasro.de

More for investors

Your next shareholder may be in another country

$36 trillion+
managed by the institutions that work with our research
70%+
of the institutions that work with our research on a company sit outside that company’s home country
172 countries
where 100,000+ professionals at 22,000+ firms have access to our research
5 million+
investors, institutional and retail, use the platforms that carry our research

Selected companies our founder has covered

What we do for a listed company

Everything here shifts the odds: keeping the investors you have and winning the ones you want.

  1. CoverageResearch deep enough for investors who have never met you.
  2. The modelEvery number and every assumption, open to you.
  3. Perception studyWhat investors say when you are not in the room.
  4. Investor webinarThe questions investors would never email, answered live.
  5. Investor roomMeetings that begin where the research ends.

Talk to us

Before every results call, walk in knowing the hardest questions.

We stay

Results, a deal, a contract, new guidance: each gets our view, from the person who knows your business, read by investors worldwide.

You stand behind your numbers. We stand behind ours.

Our only interest is that the work is right. You speak with the person who writes your coverage.

Our standard is simple: do justice to the hard work behind every company we cover, and tell every investor honestly what we find.

Dr. Javad Vaseghi

Dr. Javad Vaseghi on LinkedIn (opens in a new tab) Founder and Chief Executive Officer Member of DVFA

Talk to us

+49 (0)69 90 28 39 81 info@vasro.de

Or ask for our first view of your company